Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001446 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00001446: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001446 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001446, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer. An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as well as make correlations between the degree of angiogenesis occurring in a patient and the activity of thalidomide.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 1995-09 |
| Est. Completion | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001446
The ClinicalTrials.gov registry entry for NCT00001446 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00001446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001446 about?
NCT00001446 is a clinical study titled "A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer". This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer. An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as well as make correlations between the degree of angiogenesis...
What is the current status of trial NCT00001446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 1995-09. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00001446?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00001446?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.